Hinshaw L B
Acta Chir Scand Suppl. 1985;526:129-37.
There are no generally accepted findings to support the use of corticosteroid in cardiogenic, hemorrhagic or septic shock in the human. Furthermore, there are concerns about the safety, appropriateness and practicality of the use of corticosteroids in severe sepsis/septic shock. There is, however, abundant evidence from animal studies that large doses of corticosteroid combined with antibiotic are extremely effective in preventing or reversing the pathophysiological and lethal manifestations of E. coli-induced shock. It is important to determine if this particular therapy has human application. Results from previous clinical studies evaluating the effectiveness of corticosteroid in severe sepsis/septic shock are in marked conflict. There is now an urgent need for carefully designed clinical studies to determine if there are human subgroup populations with severe sepsis who respond similarly to the animal who can be successfully treated with high dose corticosteroid combined with conventional therapy.
目前尚无普遍公认的研究结果支持在人类心源性、出血性或感染性休克中使用皮质类固醇。此外,对于在严重脓毒症/感染性休克中使用皮质类固醇的安全性、适宜性和实用性也存在担忧。然而,动物研究有充分证据表明,大剂量皮质类固醇联合抗生素在预防或逆转大肠杆菌所致休克的病理生理和致死表现方面极为有效。确定这种特殊疗法是否适用于人类很重要。先前评估皮质类固醇在严重脓毒症/感染性休克中有效性的临床研究结果存在明显冲突。现在迫切需要精心设计的临床研究,以确定是否存在对大剂量皮质类固醇联合传统疗法有类似动物反应的严重脓毒症人类亚群。